With a recent infusion of capital and an expanded leadership team, Calhoun Vision is proceeding with efforts to usher its proprietary Light Adjustable Lens to the U.S. ophthalmology market. Rick Heinick was named Calhoun Vision president and CEO in Ma…
We now have our first FDA-approved intracorneal inlay for the surgical treatment of presbyopia, the AcuFocus Kamra inlay. I have been involved with research in the field of intracorneal lenses for the treatment of refractive errors for more than 30 years, and the journey to approval of the Kamra inlay is an enlightening example of the trials and tribulations of the innovation cycle.My first introduction to intracorneal lenses for the treatment of refractive error was at Southend-on-Sea in England in the clinic of Mr. Peter Choyce. Choyce was implanting polysulfone inlays into the cornea for the treatment of high myopia, and I saw many patients with up to –15 D of myopia have quite excellent outcomes. Further investigation also revealed many failures, with vascularization of the cornea, corneal melts and extrusion. In reviewing the literature, I learned that Jose Barraquer, MD, himself had investigated synthetic corneal inlays for the treatment of aphakia, and many other researchers, including John Henderson, MD, the former chairman at Mayo Clinic, also made similar attempts with different materials.
Intravitreal bevacizumab injections before Ahmed glaucoma valve implantation reduced postoperative hyphema and the number of glaucoma medications in patients treated for neovascular glaucoma, according to a study.Used as an adjunct to surgical procedur…
NICE, France — The second interim analysis at 3 years of the LUMINOUS study showed high diversity of baseline characteristics across distinct geographies in terms of patient age, interval from diagnosis to treatment, and prevalence of pigment epithelium detachment and polypoidal choroidal vasculopathy. “The LUMINOUS study has now reached the target enrollment of 30,000 patients. The purpose of this analysis was to describe the baseline characteristics of 17,546 patients with neovascular AMD across multiple countries recruited prior to March 2014,” Paul Mitchell, MD, said at the Euretina meeting.
NICE, France — The Euretina Lecture this year focused on cystoid maculopathies and the revolution that OCT has brought into the understanding of cystoid macular changes.The history of cystoid macular edema is closely linked to blood-retinal barrier (BRB) studies and the advent of fluorescein angiography at the end of the 1960s, Alain Gaudric, MD, emeritus professor in the Department of Ophthalmology at the Lariboisière Hospital, University of Paris 7, said.
A new study looks at risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Medscape Neurology